BioVectra recently broke ground on a new facility that will manufacture mRNA vaccines and therapeutics starting in 2023.   BioVectra’s mRNA Vaccine and Biomanufacturing Center will add 36,000 square feet to its existing Charlottetown campus and, when operational, the cGMP facility will be able produce 160 million doses of mRNA vaccine and prepare and package 70 million final vaccine doses per year for commercial distribution.   “Today is the tangible beginning to a very exciting future for o...